Glucose Baxter Holding (Glucose)

Glucose Baxter Holding is used in clinical practice to restore or maintain blood glucose levels when rapid carbohydrate delivery is required.

• Treatment of acute hypoglycemia in emergency or peri‑operative settings.
• Component of parenteral nutrition formulas for patients unable to receive enteral feeding.
• Support of intra‑operative glucose management to prevent peri‑operative metabolic disturbances.
• Provision of a glucose load for diagnostic procedures such as oral glucose tolerance tests performed intravenously.
• Dilution medium for certain intravenous medications that require a carbohydrate carrier.

Glucose Baxter Holding may be associated with a range of physiological responses, most of which reflect the rapid increase in plasma glucose after intravenous administration.

Common

• Transient hyperglycemia with elevated blood glucose measurements.
• Mild nausea or abdominal discomfort.
• Local irritation or pain at the injection site.

Serious

• Severe hyperglycemia leading to osmotic diuresis or electrolyte imbalance.
• Hypersensitivity reactions such as rash, itching, or anaphylaxis.
• Fluid overload in patients with compromised cardiac or renal function.

When administering Glucose Baxter Holding, clinicians should observe several precautionary measures to minimize risks and ensure appropriate use.

• Verify patient’s blood glucose level and clinical status before infusion.
• Adjust infusion rate in patients with diabetes, renal impairment, or heart failure.
• Use aseptic technique to prevent contamination of the sterile solution.
• Monitor electrolytes, particularly potassium and sodium, during and after administration.
• Avoid rapid large-volume infusions unless specifically indicated.
• Document the concentration and total volume administered in the medical record.

Glucose Baxter Holding can interact with other agents, influencing glucose homeostasis or fluid balance; awareness of these interactions helps guide safe co‑administration.

Avoid

• High‑dose insulin therapy without concurrent glucose monitoring.
• Large‑volume crystalloid or colloid infusions in patients prone to fluid overload.

Use with caution

• Medications that raise blood glucose (e.g., corticosteroids, catecholamines) which may exacerbate hyperglycemia.
• Drugs that affect potassium balance (e.g., beta‑agonists, diuretics) because glucose infusion can shift potassium intracellularly.
• Anticoagulants, as rapid glucose infusion may dilute plasma concentrations.